Synergy Pharmaceuticals, Inc Common Stock
SGYP
SGYP was delisted on the 7th of March, 2019.
123 hedge funds and large institutions have $431M invested in Synergy Pharmaceuticals, Inc Common Stock in 2015 Q2 according to their latest regulatory filings, with 48 funds opening new positions, 38 increasing their positions, 23 reducing their positions, and 10 closing their positions.
380% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 10
203% more capital invested
Capital invested by funds: $142M → $431M (+$289M)
65% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 23
45% more funds holding
Funds holding: 85 → 123 (+38)
13% more call options, than puts
Call options by funds: $15.8M | Put options by funds: $14M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Paulson & Co
New York
|
+$17.9M |
| 2 |
Millennium Management
New York
|
+$10.4M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$9.74M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$9.54M |
| 5 |
YCMGA
York Capital Management Global Advisors
New York
|
+$8.97M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1.8M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.07M |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
-$1.06M |
| 4 |
PC
Polar Capital
London,
United Kingdom
|
-$846K |
| 5 |
DS
DRW Securities
Chicago,
Illinois
|
-$739K |
SGYP Hedge Fund Activity: Q2 2015 in Review
123 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Synergy Pharmaceuticals, Inc Common Stock (SGYP) for Q2 2015, worth a combined $431M — up 203% from $142M a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new SGYP positions and 10 closed out — a net gain of 38 holders — while 38 added to existing stakes and 23 trimmed.
The largest buyer was Paulson & Co, adding an estimated $17.9M. The largest seller was Morgan Stanley, cutting an estimated $1.8M.
- 123 institutional investors held Synergy Pharmaceuticals, Inc Common Stock (SGYP) as of Q2 2015, up from 85 in Q1 2015.
- Funds reported $431M of Synergy Pharmaceuticals, Inc Common Stock stock for Q2 2015, up 203% quarter-over-quarter.
- 48 funds opened new Synergy Pharmaceuticals, Inc Common Stock positions in Q2 2015 and 10 closed out, a net change of +38 holders.
- The largest Synergy Pharmaceuticals, Inc Common Stock buyer in Q2 2015 was Paulson & Co, an estimated $17.9M added.
- The largest Synergy Pharmaceuticals, Inc Common Stock seller in Q2 2015 was Morgan Stanley, an estimated $1.8M sold.
Based on aggregated 13F filings for Q2 2015.